Intracavitary Therapeutics for Pleural Malignancies

Vivek Murthy; Keshav Mangalick; Daniel H. Sterman

doi:10.1016/j.ccm.2017.11.003

Intracavitary Therapeutics for Pleural Malignancies

Vivek Murthy, Keshav Mangalick, Daniel H. Sterman

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.

Original language	English (US)
Pages (from-to)	195-209
Number of pages	15
Journal	Clinics in Chest Medicine
Volume	39
Issue number	1
DOIs	https://doi.org/10.1016/j.ccm.2017.11.003
State	Published - Mar 2018
Externally published	Yes

Keywords

Intracavity therapeutics
Mesothelioma
Pleural malignancies
Pleural space

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.ccm.2017.11.003

Cite this

@article{2cde98719c0b46fdb8fbf65b3b88a60f,

title = "Intracavitary Therapeutics for Pleural Malignancies",

abstract = "Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.",

keywords = "Intracavity therapeutics, Mesothelioma, Pleural malignancies, Pleural space",

author = "Vivek Murthy and Keshav Mangalick and Sterman, {Daniel H.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2018",

month = mar,

doi = "10.1016/j.ccm.2017.11.003",

language = "English (US)",

volume = "39",

pages = "195--209",

journal = "Clinics in Chest Medicine",

issn = "0272-5231",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Intracavitary Therapeutics for Pleural Malignancies

AU - Murthy, Vivek

AU - Mangalick, Keshav

AU - Sterman, Daniel H.

PY - 2018/3

Y1 - 2018/3

N2 - Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.

AB - Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.

KW - Intracavity therapeutics

KW - Mesothelioma

KW - Pleural malignancies

KW - Pleural space

UR - http://www.scopus.com/inward/record.url?scp=85039043785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039043785&partnerID=8YFLogxK

U2 - 10.1016/j.ccm.2017.11.003

DO - 10.1016/j.ccm.2017.11.003

M3 - Review article

C2 - 29433715

AN - SCOPUS:85039043785

SN - 0272-5231

VL - 39

SP - 195

EP - 209

JO - Clinics in Chest Medicine

JF - Clinics in Chest Medicine

IS - 1

ER -

Intracavitary Therapeutics for Pleural Malignancies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this